"Myasthenia Gravis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A disorder of neuromuscular transmission characterized by weakness of cranial and skeletal muscles. Autoantibodies directed against acetylcholine receptors damage the motor endplate portion of the NEUROMUSCULAR JUNCTION, impairing the transmission of impulses to skeletal muscles. Clinical manifestations may include diplopia, ptosis, and weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles. THYMOMA is commonly associated with this condition. (Adams et al., Principles of Neurology, 6th ed, p1459)
| Descriptor ID |
D009157
|
| MeSH Number(s) |
C10.114.656 C10.668.758.725 C20.111.258.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Myasthenia Gravis".
Below are MeSH descriptors whose meaning is more specific than "Myasthenia Gravis".
This graph shows the total number of publications written about "Myasthenia Gravis" by people in this website by year, and whether "Myasthenia Gravis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 2 | 0 | 2 |
| 2001 | 3 | 0 | 3 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 3 | 0 | 3 |
| 2006 | 2 | 0 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 3 | 0 | 3 |
| 2018 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 2 | 0 | 2 |
| 2022 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myasthenia Gravis" by people in Profiles.
-
Management of respiratory failure in immune checkpoint inhibitors-induced overlap syndrome: a case series and review of the literature. BMC Anesthesiol. 2023 09 12; 23(1):310.
-
Delayed Diagnosis of Thymoma in Ocular Myasthenia Gravis. J Neuroophthalmol. 2024 Sep 01; 44(3):e419-e420.
-
Point Counter-Point: Thymectomy in Ocular Myasthenia Gravis. J Neuroophthalmol. 2022 12 01; 42(4):541-546.
-
Functional Impairments and Rehabilitation Outcomes of Patients With Immunotherapy-Induced Acute Inflammatory Demyelinating Polyradiculoneuropathy, Myasthenia Gravis, and Myositis. Am J Phys Med Rehabil. 2021 10 01; 100(10):1015-1019.
-
Ocular Myasthenia Gravis 32 years From Remission to Relapse. J Neuroophthalmol. 2023 06 01; 43(2):e45-e46.
-
Critically ill patients with severe immune checkpoint inhibitor related neurotoxicity: A multi-center case series. J Crit Care. 2021 10; 65:126-132.
-
Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors. Arthritis Rheumatol. 2021 05; 73(5):866-874.
-
Pediatric Autoimmune Ocular Myasthenia Gravis: Evaluation of Presentation and Treatment Outcomes in a Large Cohort. Pediatr Neurol. 2021 05; 118:12-19.
-
Minimal manifestation status and prednisone withdrawal in the MGTX trial. Neurology. 2020 08 11; 95(6):e755-e766.
-
Immunotherapy-related skeletal muscle weakness in cancer patients: a case series. Ann Palliat Med. 2021 Feb; 10(2):2359-2365.